Role of ubiquitin-proteasome system (UPS) in left ventricular hypertrophy (LVH).
- 15 January 2014
- journal article
- review article
- Vol. 4 (1), 1-5
Abstract
Cardiac hypertrophy is a key compensatory mechanism acting in response to pressure or volume overload, involving some alterations in signaling transduction pathways and transcription factors-regulation. These changes result in enhanced proteins' synthesis leading to Left Ventricular Hypertrophy (LVH). It is known that the main function of Ubiquitin-Proteasome System (UPS) is to prevent accumulation of damaged, misfolded and mutant proteins by proteolysis. But emerging evidences suggest that UPS also attends to the cells' growth, favoring proteins' synthesis, subsequently evolving in LVH. The role of the proteasome in to favor cellular hypertrophy consists in upregulation of the catalytic proteasome subunit, with prevalence of proteins-synthesis on proteins degradation. It is also evident that UPS inhibition may prevent cells' growth opposing to the hypertrophy. In fact in several experimental models, UPS inhibition demonstrated to be able to prevent or reverse cardiac hypertrophy induced by abdominal aortic banding (AAB). That can happen with several proteasome inhibitors acting by multifactorial mechanisms. These evidences induce to hypothesize that, in the future, in patients with the increased volume overload by systemic hypertension, some proteasome-inhibitors could be used to antagonize or prevent LVH without reducing peripheral high blood pressure levels too.Keywords
This publication has 34 references indexed in Scilit:
- Molecular and Clinical Aspects of Proteasome Inhibition in the Treatment of CancerRecent Results in Cancer Research, 2007
- Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular HypertrophyCirculation, 2006
- The ubiquitin–proteasome system: Focus on the heartCardiovascular Research, 2006
- The Murine Cardiac 26S Proteasome: An Organelle Awaiting ExplorationAnnals of the New York Academy of Sciences, 2005
- Endoplasmic reticulum-associated protein degradation—one model fits all?Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2004
- Protein degradation and protection against misfolded or damaged proteinsNature, 2003
- Proteasome inhibition ablates activation of NF-κB in myocardial reperfusion and reduces reperfusion injuryAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- Degradation of oxidized proteins by the 20S proteasomeBiochimie, 2001
- A Subcomplex of the Proteasome Regulatory Particle Required for Ubiquitin-Conjugate Degradation and Related to the COP9-Signalosome and eIF3Cell, 1998